HAYWARD, Calif. & FORT COLLINS, Colo.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) and TOLMAR, Inc. today announced that they will collaborate on a multiproduct agreement for the development, supply and distribution of alternative dosage form products. The targeted products had over $1 billion in brand sales in 2011, with several of the products having first-to-file or first-to-market potential. The products and terms of the agreement were not disclosed.
